Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MORAb-202 in Selected Folate Receptor Alpha–Expressing Tumors
jRCT2031250488Phase 2Recruiting
- Sponsor
- Eisai Co., Ltd.
- Start
- Nov 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
A Phase 2 trial of farletuzumab ecteribulin in Serous Papillary Cystadenocarcinoma, primary peritoneal cancer (PPC), fallopian tube cancer (PFTC), endometrial cancer (EC), triple-negative breast cancer (TNBC), sponsored by Eisai Co., Ltd.. Started Nov 2025; status: recruiting.
02
Drugs
farletuzumab ecteribulin
03
Conditions
Serous Papillary Cystadenocarcinomaprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)endometrial cancer (EC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on jRCT2031250488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250488.